On May 12, 2025, Sangamo Therapeutics, Inc. entered into an underwriting agreement for an Offering of 12,235,000 shares of common stock and pre-funded warrants, expecting to raise approximately $23 million. The Offering is set to close on May 14, 2025, pending customary conditions.